A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Clinical trial NCT06022029 · RECRUITING

Trial details

NCT number: NCT06022029
Sponsor: OncoNano Medicine, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Triple Negative Breast Cancer Diffuse Large B Cell Lymphoma Follicular Lymphoma Lymphoma, Non-Hodgkin Mantle Cell Lymphoma Bladder Cancer Uveal Melanoma, Recurrent Cervix Cancer Carcinoma in Situ Head and Neck Squamous Cell Carcinoma Skin Cancer Metastatic Cancer

Start date: 2023-10-13
Primary completion: 2026-04-30
Enrollment: 168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.